Skip to main content
Erschienen in:

06.01.2022 | Original Article

Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India

verfasst von: Sinjini Sarkar, Pranab K. Sahoo, Ranita Pal, Tanuma Mistry, Sutapa Mahata, Puja Chatterjee, Manisha Vernekar, Syamsundar Mandal, Tanmoy Bera, Vilas D. Nasare

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The study aims to record the quality of life (Qol) and its changes while ovarian cancer (OC) patients undergo debulking surgeries and chemotherapy in a tertiary care hospital of Eastern India.

Methods

Patients with advanced epithelial OC (FIGO stages III–IV) were recruited. They underwent primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri-weekly doses of paclitaxel + carboplatin. QoL was assessed using Fact- O + FACIT-Sp-12 questionnaire with a set of 51 questions in different domains (spiritual, physical, social, emotional, and functional factors) and a special set for OC patients under the heading “Additional concerns.” The responses from patients were recorded at baseline (diagnosis/study entry), 2, 4, and 6 months during the treatment visits. Overall survival (OS) was assessed using Kaplan Meier curve.

Results

A majority of patients were 49.15±10.8 years of age, school-educated (54%), unemployed/homemakers (73.5%), belonging from rural setup (64.6%) with a monthly income of Rs. 2000/- to Rs. 5000/-. There was no statistically significant (p>0.05) improvement found in Qol from the baseline till the end of the study, neither overall nor in subsets (responders (Rs)/partial responders (PRs)/non-responder (NRs) groups or the adjuvant and neoadjuvant chemotherapy groups). The common toxicities like anemia, constipation, and weight loss were significantly (p<0.05) correlated with the patients’ physical, functional, emotional, and social well-being.

Conclusion

Ovarian cancer patients represent a poor functional, social, and disease-specific quality of life that needs to be addressed, identified, and improved by the growing nexus of healthcare providers and researchers.
Literatur
1.
Zurück zum Zitat Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020) Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon, France Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020) Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon, France
2.
Zurück zum Zitat Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA (2012) Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem 60(1):9–21CrossRef Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA (2012) Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem 60(1):9–21CrossRef
3.
Zurück zum Zitat Gajjar K, Ogden G, Mujahid MI, Razvi K (2012) Symptoms and risk factors of ovarian cancer: a survey in primary care. ISRN Obstet Gynecol. 2012:754197CrossRef Gajjar K, Ogden G, Mujahid MI, Razvi K (2012) Symptoms and risk factors of ovarian cancer: a survey in primary care. ISRN Obstet Gynecol. 2012:754197CrossRef
5.
Zurück zum Zitat Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E (2018) Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol 19(8):1126–1134. https://doi.org/10.1016/S1470-2045(18)30343-7CrossRefPubMedPubMedCentral Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E (2018) Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol 19(8):1126–1134. https://​doi.​org/​10.​1016/​S1470-2045(18)30343-7CrossRefPubMedPubMedCentral
6.
7.
Zurück zum Zitat Grzankowski KS, Carney M (2011) Quality of life in ovarian cancer. Cancer Control. 18(1):52–8CrossRef Grzankowski KS, Carney M (2011) Quality of life in ovarian cancer. Cancer Control. 18(1):52–8CrossRef
9.
Zurück zum Zitat Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, Lesoin A, Zannetti A, N’Guyen S, Trager-Maury S, Chauvenet L, AbadieLacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P (2019) Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. Ann Oncol. 30(5):845–852. https://doi.org/10.1093/annonc/mdz074CrossRefPubMed Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, Lesoin A, Zannetti A, N’Guyen S, Trager-Maury S, Chauvenet L, AbadieLacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P (2019) Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. Ann Oncol. 30(5):845–852. https://​doi.​org/​10.​1093/​annonc/​mdz074CrossRefPubMed
10.
Zurück zum Zitat Chase DM, Wenzel L (2011) Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res 11(4):421–431CrossRef Chase DM, Wenzel L (2011) Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res 11(4):421–431CrossRef
11.
Zurück zum Zitat Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D, Gynecologic Cancer Intergroup Study of NCIC Clinical Trials Group (NCIC CTG), European Organization for Research and Treatment of Cancer - Gynecologic Cancer Group (EORTC-GCG), Grupo de Investigación de Cáncer de Ovario (GEICO) (2016) Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer 24(3):1241–9CrossRef Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D, Gynecologic Cancer Intergroup Study of NCIC Clinical Trials Group (NCIC CTG), European Organization for Research and Treatment of Cancer - Gynecologic Cancer Group (EORTC-GCG), Grupo de Investigación de Cáncer de Ovario (GEICO) (2016) Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer 24(3):1241–9CrossRef
12.
Zurück zum Zitat Schipper H, Clinch JJ, Olweny CLM (1996) Quality of life studies: Definitions and conceptual issues. In: Spilker B (ed) Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Lippincott-Raven Publishers, Philadelphia, pp 11–23 Schipper H, Clinch JJ, Olweny CLM (1996) Quality of life studies: Definitions and conceptual issues. In: Spilker B (ed) Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Lippincott-Raven Publishers, Philadelphia, pp 11–23
13.
Zurück zum Zitat Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059CrossRef Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059CrossRef
19.
Zurück zum Zitat von Gruenigen VE, Huang HQ, Gil KM et al (2010) A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage 39(5):839–846CrossRef von Gruenigen VE, Huang HQ, Gil KM et al (2010) A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage 39(5):839–846CrossRef
20.
Zurück zum Zitat Holzner B, Kemmler G, Greil R et al (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13(6):965–73CrossRef Holzner B, Kemmler G, Greil R et al (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13(6):965–73CrossRef
Metadaten
Titel
Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India
verfasst von
Sinjini Sarkar
Pranab K. Sahoo
Ranita Pal
Tanuma Mistry
Sutapa Mahata
Puja Chatterjee
Manisha Vernekar
Syamsundar Mandal
Tanmoy Bera
Vilas D. Nasare
Publikationsdatum
06.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06735-3

Neu im Fachgebiet Onkologie

ctDNA erkennt minimale Resterkrankung beim Melanom

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Ringen um den richtigen Umgang mit Zufallsbefunden

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.